Results 101 to 110 of about 560,406 (374)

Identifying prognostic targets in metastatic prostate cancer beyond AR

FEBS Open Bio, EarlyView.
Genome‐wide functional screens combined with a large gene expression database and clinical outcomes can identify new therapeutic vulnerabilities in prostate cancer. Eight potentially druggable targets demonstrated strong dependency in cell lines, were associated with worse prognosis clinically, and showed evidence of protein expression in prostate ...
Emily Feng, Eric Feng, Tracy Berg, Isabella S. Nguyen, Lilac G. Nguyen, William Chen, Meng Zhang, David Quigley, Marina Sharifi, Haolong Li, Ilsa Coleman, Peter S. Nelson, Martin Sjöström, Shuang G. Zhao   +13 more
wiley   +1 more source

Treatment-Related Decisional Conflict, Quality of Life, and Comorbid Illness in Older Adults with Cancer [PDF]

, 2017
As the aging population in the nation increases, cancer diagnoses in this age group will also increase. The many chronic medical conditions associated with older adults are confounded by a diagnosis of cancer.
Kates, PhD, MSN, GNP-BC, Jeannette
core   +1 more source

Understanding and Overcoming Immunotherapy Resistance in Skin Cancer: Mechanisms and Strategies

Aging and Cancer, EarlyView.
This narrative review explores the mechanisms driving immunotherapy resistance in skin cancer, including tumor microenvironment factors, genetic mutations, and immune evasion strategies. It highlights potential strategies to overcome resistance, offering insights for improving therapeutic outcomes and guiding future research in personalized ...
Shreya Singh Beniwal, Abhimanyu Chiraparambil Radhakrishnan, Ayanchetty Haripraba, Saif Syed, Gajawada Pragna, Ayush Dwivedi, Akash Rawat, Daniela Castro Calderón, Martin Cevallos‐Cueva   +8 more
wiley   +1 more source

Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2020 edition)

Precision Radiation Oncology, 2021
Jun Wang, Baosheng Li, Chinese Association for Therapeutic Radiation Oncologists, China Society for Radiation Oncology, Chinese Association of Radiation Therapy   +2 more
doaj   +1 more source

ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial

Radiation Oncology, 2018
Background Stereotactic body radiotherapy (SBRT) is an emerging treatment alternative for patients with localized prostate cancer. Promising results in terms of disease control and toxicity have been reported with 4 to 5 SBRT fractions. However, question
Thomas Zilli, Marta Scorsetti, Daniel Zwahlen, Ciro Franzese, Robert Förster, Niccolò Giaj-Levra, Nikolaos Koutsouvelis, Aurelie Bertaut, Michel Zimmermann, Giuseppe Roberto D’Agostino, Filippo Alongi, Matthias Guckenberger, Raymond Miralbell   +12 more
doaj   +1 more source

Focal Spot, Spring 2005 [PDF]

, 2005
https://digitalcommons.wustl.edu/focal_spot_archives/1099/thumbnail ...

core   +1 more source

Emerging Cybersecurity Threats in Radiation Oncology

Advances in Radiation Oncology, 2021
Purpose: Modern image guided radiation therapy is dependent on information technology and data storage applications that, like any other digital technology, are at risk from cyberattacks.
Christine Joyce, BS, Faustin Laurentiu Roman, MSc, Brett Miller, MS, MBA, John Jeffries, BS, Robert C. Miller, MD, MBA, FASTRO   +4 more
doaj  

Empowering patients in decision‐making in radiation oncology – can we do better?

Molecular Oncology, 2020
The decision as to whether or not a patient should receive radiation therapy as part of their cancer treatment is based on evidence‐based practice and on recommended international consensus treatment guidelines.
Michelle Leech, Matthew S. Katz, Joanna Kazmierska, Julie McCrossin, Sandra Turner   +4 more
doaj   +1 more source

Focal Spot, Summer 2001 [PDF]

, 2001
https://digitalcommons.wustl.edu/focal_spot_archives/1088/thumbnail ...

core   +1 more source

Textbook of Radiation Oncology [PDF]

British Journal of Cancer, 2005
The second edition of this textbook, published 6 years after the first, is edited by two eminent radiation oncologists from the Memorial Sloan-Kettering Cancer Centre, New York, and the University of California, San Francisco. The editors state that their aim was to use contributors that had connections with these institutions in order to present a ...
openaire   +1 more source